Guggenheim Securities Initiates Sucampo Pharmaceuticals With Buy

Analysts at Guggenheim Securities initiated coverage on

with a Buy rating. The target price for Sucampo Pharmaceuticals is set to $23. Sucampo Pharmaceuticals shares have gained 123.22% over the past 52 weeks, while the S&P 500 index has surged 10.82% in the same period. Sucampo Pharmaceuticals' shares fell 0.38% to close at $15.67 on Thursday.